FA
MREO

Forefront Analytics’s Mereo BioPharma MREO Stock Holding History

Forefront Analytics’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$42.2K Buy
127,778
+96,010
+302% +$41.2K 0.04% 39
2025
Q4 		$13.2K Sell
31,768
-1,412
-4% -$2.69K 0.01% 43
2025
Q3 		$68.4K Buy
33,180
+14,042
+73% +$25.9K 0.07% 42
2025
Q2 		$51.9K Sell
19,138
-28,492
-60% -$68.8K 0.06% 41
2025
Q1 		$107K Buy
47,630
+12,877
+37% +$36.4K 0.12% 38
2024
Q4 		$122K Buy
34,753
+953
+3% +$3.74K 0.06% 56
2024
Q3 		$139K Sell
33,800
-2,431
-7% -$10.1K 0.07% 58
2024
Q2 		$130K Sell
36,231
-7,586
-17% -$24.6K 0.06% 61
2024
Q1 		$145K Buy
43,817
+7,693
+21% +$26K 0.07% 56
2023
Q4 		$83.4K Sell
36,124
-29,525
-45% -$56.5K 0.04% 62
2023
Q3 		$84.7K Sell
65,649
-17,100
-21% -$22.7K 0.05% 56
2023
Q2 		$109K Sell
82,749
-951
-1% -$1.1K 0.06% 55
2023
Q1 		$59.2K Buy
83,700
+10,200
+14% +$9.18K 0.03% 67
2022
Q4 		$55.1K Sell
73,500
-39,300
-35% -$32.3K 0.03% 67
2022
Q3 		$96K Buy
112,800
+36,950
+49% +$45.2K 0.05% 52
2022
Q2 		$83K Buy
+75,850
New +$58.8K 0.04% 53

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

Forefront Analytics's MREO Position: Q1 2026 in Review

Forefront Analytics increased its Mereo BioPharma (MREO) stake by 302% in Q1 2026, buying an estimated $41.2K and bringing the position to 127,778 shares worth $42.2K. The position accounts for 0.04% of the portfolio, ranked #39.

Forefront Analytics first reported a position in MREO in Q2 2022 and has held it in 16 quarters since. The position peaked at $145K in Q1 2024. 63 funds tracked by Wall St. Rank hold MREO as of Q1 2026.

  • Forefront Analytics held 127,778 shares of Mereo BioPharma worth $42.2K as of Q1 2026.
  • Forefront Analytics bought 96,010 Mereo BioPharma shares in Q1 2026, an estimated $41.2K.
  • Mereo BioPharma made up 0.04% of Forefront Analytics's portfolio in Q1 2026, its #39 holding.
  • Forefront Analytics first reported a position in Mereo BioPharma in Q2 2022 and has held it in 16 quarters since.
  • Forefront Analytics's Mereo BioPharma position peaked at $145K in Q1 2024.
  • 63 funds tracked by Wall St. Rank held Mereo BioPharma as of Q1 2026.

Based on Forefront Analytics's 13F filing for Q1 2026, filed 13 May 2026.